Access to Medical Treatments (Innovation) Bill (Money) Debate

Full Debate: Read Full Debate
Department: Department of Health and Social Care

Access to Medical Treatments (Innovation) Bill (Money)

Jim Shannon Excerpts
Tuesday 3rd November 2015

(8 years, 6 months ago)

Commons Chamber
Read Full debate Read Hansard Text Read Debate Ministerial Extracts
Jim Shannon Portrait Jim Shannon (Strangford) (DUP)
- Hansard - -

I, too, have concerns about the Bill introduced by the hon. Member for Daventry (Chris Heaton-Harris). I agree in principle about the need for quick, easy and affordable access to effective treatments for patients, and new developments and initiatives that improve access to innovative treatments should be encouraged so long as they do not have a negative impact on patient safety. The hon. Member for Totnes (Dr Wollaston) made that point, as did other Members.

Questions and concerns have been raised by a number of prominent UK charities—the British Heart Foundation, Prostate Cancer UK and Alzheimer’s Research UK, to name but a few. We must be careful not to confuse intention with outcome. The main concern is the potential risk to medical research, and the Association of Medical Research Charities, which represents a large number of prominent and well-respected medical charities, has expressed concern that

“the bill may inadvertently act to discourage patients from participating in robust research studies”.

That is important, and we must be clear that we are concerned about introducing legislation that has perhaps not been fully thought out.

Further concerns include the vagueness of certain definitions in the Bill. For example, what exactly can be described as “accepted medical treatments”? Well-respected UK charities in the sector have expressed concern about the vagueness of that definition, and it is just one of many concerns.

The Bill is loose and it is not definitive. It is also unclear. With great respect to the hon. Member for Daventry, we need to go back to the drawing board with this one. In addition to concerns about unintended consequences, there is the question of whether the Bill is really necessary. I reiterate my support for innovation as a principle—it should be encouraged and welcomed—but I want the House to note the comments that many hon. Members have made today and be mindful of the concerns that have been raised, because we do not want the Bill, however well intended, to have unintended negative consequences.